BioSpace News Archive

Pliant Therapeutics, Inc. today announced Ms. Lily Cheung as its Chief Human Resources Officer.

Vaginal discomfort is one of the leading reasons women seek healthcare advice, and over 90% of these cases can be attributed to imbalances in the vaginal microbiome.

Children’s Hospital Los Angeles (CHLA) has launched the first clinical trial for Down syndrome regression disorder (DSRD), a rare and debilitating condition that affects adolescents and young adults with Down syndrome.

Nascent Biotech, Inc. announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab as a treatment for Brain Cancer.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the publication of a preclinical study demonstrating delta-like ligand 3 (DLL3) is a promising tumor target for AlloCAR T™ in small cell lung cancer (SCLC).

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the required procedure of registering the source of the active pharmaceutical ingredient (API) of crofelemer with the Agenzia Italiana Del Farmaco (AIFA), the Italian Medicines Agency, has been successfully completed.

Enlivex Therapeutics Ltd. today announced that an independent Data and Safety Monitoring Board (DSMB) has completed its prespecified data review for the first cohort of patients in the Company’s ongoing Phase I/II cell therapy clinical trial of Allocetra TM in patients with advanced-stage solid tumors.

Adhera Therapeutics, Inc. (OTCQB: ATRX) (“Adhera” or the “Company”), a clinical stage biopharmaceutical company, is pleased to announce that the Company is to commence a dose finding study of MLR-1023 (tolimidone) in Type 1 Diabetes in collaboration with the Alberta Diabetes Institute (“ADI”) at the University of Alberta (“U of A”), located in Edmonton, Alberta, Canada.

Acasti Pharma Inc. announces that it has received notification from the NASDAQ Listing Qualifications Department (“NASDAQ”) that it is eligible for an additional 180 calendar days, or until July 24, 2023, to regain compliance with the minimum $1.00 per share requirement.

Juno Diagnostics™ (JunoDx™), a company focused on bringing vital health information to patients by improving access, affordability, and transparency, today announced it will participate at the Precision Medicine World Conference (PMWC), held January 25-27, 2023, in Santa Clara, CA.